# Shifamed

> Shifamed is a Silicon Valley medical technology incubator founded in 2009 by serial entrepreneur Amr Salahieh. It combines human-centered design, in-house engineering, and R&D facilities to build medical device companies from concept to commercial launch, spinning out and incubating startups across cardiovascular, electrophysiology, and ophthalmology. Its portfolio and legacy companies have raised over $800M and produced multiple acquisitions by Boston Scientific, Abbott, Covidien, and Johnson & Johnson.

- **Founded:** 2009
- **Headquarters:** Campbell, California, United States
- **Founders:** Amr Salahieh (Founder & CEO)
- **Team size:** ~85 employees
- **Products:** Medical device incubation, In-house R&D and engineering services, Supira Medical (portfolio), Atia Vision (portfolio), Akura Medical (portfolio)
- **Notable:** Founder Amr Salahieh named inventor/co-inventor on 400+ issued and pending patents worldwide, Over $800M raised across the portfolio to date, Multiple acquisitions by Boston Scientific, Abbott, Covidien, and Johnson & Johnson

## Products & services

- **Medical device incubation** — End-to-end venture building for medtech startups - concept, engineering, prototyping, regulatory strategy, and financing under one roof.
- **In-house R&D and engineering services** — Specialized engineering and human-centered design facilities used to develop portfolio company products.
- **Supira Medical (portfolio)** — Next-generation percutaneous ventricular assist device (pVAD) for high-risk patients and cardiogenic shock.
- **Atia Vision (portfolio)** — OmniVu dual-optic accommodating intraocular lens for cataract patients; FDA-cleared for US clinical trials in 2025.
- **Akura Medical (portfolio)** — Differentiated approach to treating venous thromboembolism (VTE).
- **Laza Medical (portfolio)** — AI- and robotics-enabled imaging solution for cardiac interventions.

## Achievements

- Founder Amr Salahieh named inventor/co-inventor on 400+ issued and pending patents worldwide
- Over $800M raised across the portfolio to date
- Multiple acquisitions by Boston Scientific, Abbott, Covidien, and Johnson & Johnson
- Atia Vision's OmniVu lens cleared by FDA to begin US clinical trials (2025)
- Supira Medical received FDA Breakthrough Device Designation

## Latest updates

- **2025-05** — Atia Vision, a Shifamed portfolio company, received FDA approval to begin a US clinical study of its OmniVu accommodating intraocular lens.
- **2023-11** — Supira Medical received FDA Breakthrough Device Designation and closed $40M in Series D financing.
- **2023** — Laza Medical closed $36M Series A to develop AI- and robotics-enabled cardiac imaging.
- **2022** — Akura Medical closed $35M Series B for its venous thromboembolism therapy.

## Links

- Website: https://shifamed.com
- LinkedIn: https://www.linkedin.com/company/shifamed
- Twitter/X: https://twitter.com/shifamed

---

Profile page: https://yespress.io/shifamed
Published by YesPress — https://yespress.io
Last updated: 2026-07-10